Investment Rating - The report initiates coverage with an "Accumulate" rating for Samsung Medical (601567.SH) [1][3] Core Insights - Samsung Medical has established a dual business model focusing on smart power distribution and medical services, maintaining a leading and stable market share in the domestic power distribution sector while expanding its overseas presence in Europe, the Middle East, and Latin America [1][7] - The company is well-positioned to benefit from the high demand for smart power distribution overseas, particularly in Europe, where the penetration rate of smart meters is still low, presenting significant growth opportunities [7][30] - The domestic power distribution market is expected to accelerate, with the company maintaining a strong competitive position and benefiting from ongoing network upgrades [7][41] - The rehabilitation medical sector is identified as a blue ocean market, with the company expanding its network of rehabilitation hospitals in response to increasing domestic demand [7][18] Financial Data and Valuation - Total revenue is projected to grow from 11,463 million yuan in 2023 to 21,506 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 18% [2] - Operating profit is expected to increase from 2,270 million yuan in 2023 to 3,008 million yuan in 2027, with a notable growth of 97% in 2023 [2] - Net profit attributable to shareholders is forecasted to rise from 1,904 million yuan in 2023 to 2,576 million yuan in 2027, reflecting a growth of 101% in 2023 [2] - The company’s price-to-earnings (PE) ratio is projected to decrease from 19.7 in 2023 to 14.6 in 2027, indicating an improving valuation [2] Company Overview - Samsung Medical was established in 2007, evolving from a company with over 30 years of experience in the electric meter industry, and has since diversified into power distribution and medical services [11][12] - The company has a concentrated ownership structure, with the founder and chairman holding over 40% of the shares [12][15] Business Segments - The smart power distribution segment accounts for approximately 80% of total revenue, with a consistent growth rate of 20-30% since 2022 [18][22] - The medical services segment is expanding through investments and acquisitions, with a focus on high-quality rehabilitation services [18][24] Market Dynamics - The overseas demand for power distribution is robust, with significant investments planned in the European power grid, particularly in modernization and digitalization [41][43] - Emerging markets are experiencing rapid infrastructure development, with increasing participation from Chinese companies in projects across Latin America and the Middle East [46][48]

Core Viewpoint - The recent surge in A-share stocks related to the power grid indicates a strong market sentiment towards the electric power sector, driven by favorable government policies and significant investment plans [1][3]. Group 1: Market Performance - In recent trading days, A-share stocks related to the power grid have shown a continuous upward trend, with multiple stocks hitting the daily limit up [1][3]. - On March 6, stocks such as New Energy Taishan and Guangdian Electric reached their daily limit, contributing to a broader rally in the sector [1][3]. Group 2: Government Policies and Investment Plans - The government work report emphasizes the construction of a new power system and the acceleration of smart grid development, which is expected to boost the sector [2][4]. - The State Grid announced a fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan, representing a 40% increase compared to the previous plan, with an average annual investment of 800 billion yuan [2][4]. - The Southern Power Grid is projected to invest around 1 trillion yuan during the same period, leading to a total investment of nearly 5 trillion yuan from both major grids [4][5]. Group 3: Future Projections and Industry Trends - The State Grid plans to implement ten initiatives to support the high-quality development of new energy, including the operation of 15 ultra-high voltage direct current projects and a 35% increase in inter-provincial transmission capacity [4][5]. - By 2030, the operational and under-construction pumped storage capacity is expected to exceed 120 million kilowatts, with renewable energy generation accounting for over 30% of the total in the operational area [5]. - Global investment in power grids is rapidly increasing, with projections of reaching $390 billion in 2024 and exceeding $400 billion in 2025 [7]. - The demand for electricity from data centers is expected to rise significantly, with a forecasted increase from 415 TWh in 2024 to 945 TWh by 2030, indicating a growing need for infrastructure upgrades [7]. Group 4: International Developments - In the U.S., a new investment cycle in the power system is underway, driven by increased electricity demand from the AI industry, which may lead to a shortage of high-voltage equipment [8]. - The Texas and Mid-Atlantic regions are advancing transmission expansion plans totaling $75 billion, focusing on building ultra-high voltage AC lines to enhance grid reliability [7][8].

Summary of Conference Call Notes Company and Industry Involved - The company discussed is **Samsung Medical**, specifically its subsidiary **Samsung Sweden** which has secured contracts for transformer manufacturing. - The industry focus is on **transformer manufacturing** and **power distribution technology**. Core Points and Arguments - Samsung Sweden has signed a framework contract with **Enexis** in the Netherlands for oil-immersed transformers, amounting to **€117 million**, approximately **¥949 million** [1] - Winning the Dutch contract indicates that Samsung's transformer manufacturing capabilities have met **global high-level certifications**, particularly due to stringent EU standards on **environmental protection**, **energy efficiency**, and **noise reduction** [1] - The company’s distribution technology is beginning to lead in overseas markets, surpassing many domestic competitors [1] Additional Important Content - The company has progressively secured contracts, starting with a **¥341 million** order for oil-immersed transformers in Brazil in 2023, followed by a **¥466 million** contract with the Greek power authority (HEDNO) in April 2024, culminating in the recent Dutch order [2] - This sequence of contracts signifies that the company's technological strength is gaining **global recognition**, moving from simpler to more complex projects [2] - Market perception is shifting positively towards **Siyuan Electric** in the mid-to-high voltage overseas market, suggesting that Samsung could become a comparable player in the international distribution system [2] - Profit forecasts for 2026 are projected at **¥2.3-2.4 billion**, with a current price-to-earnings ratio of **16x**, while Siyuan is expected to have a **45x** ratio, indicating that Samsung is significantly undervalued and warrants continued attention [2]

Summary of Conference Call Notes Company and Industry Involved - **Company**: 长江电新 (Changjiang Electric New) - **Industry**: Transformer manufacturing and distribution, specifically in the high-end market segment in Europe Core Points and Arguments 1. **Contract Announcement**: On March 5, the company announced the signing of a transformer framework contract with the Netherlands' Enexis electricity bureau, totaling €117 million, approximately ¥949 million [1] 2. **Market Position**: Enexis is a major distribution system operator (DSO) in the Netherlands, which is a significant transformer manufacturing country in Europe. The company won this project with a top comprehensive ranking, marking its first breakthrough in the high-end market in Western Europe [1] 3. **Significance of the Win**: - **Market Recognition**: The company secured the contract at a relatively high price, indicating that both the company and Chinese transformers have gained recognition in the global top-tier market, with expectations for continued breakthroughs in high-end markets [1] - **Capacity Assurance**: There is a sustained tight demand for transformers overseas, with a projected 35% increase in transformer exports from the Netherlands to the U.S. by 2025. The company has sufficient capacity to meet European demand [1] 4. **High Gross Margin**: The framework order has a high gross margin level, initially fulfilled by domestic production capacity, with plans for local production in Europe once the distribution capacity is operational [2] 5. **Market Outlook**: The global transformer market is experiencing a continuous upturn, and as a leading domestic distribution transformer enterprise, the company is expected to continue securing orders in high-end markets such as Europe and North America [2] 6. **Financial Projections**: The company is projected to achieve a net profit attributable to shareholders of ¥2.2 billion by 2026, corresponding to a price-to-earnings (PE) ratio of only 17 times, indicating significant revaluation potential [2] Other Important but Possibly Overlooked Content - The strategic importance of entering the European market and the implications for future growth and competitiveness in the global transformer industry [1][2]

Key Points - The 2025 annual revenue of JD Group is projected to be 1.31 trillion yuan, representing a year-on-year increase of 13% [5] - Silver Wheel Co., Ltd.'s subsidiary has secured a contract with an international client, expecting annual sales of approximately 131 million USD [6] - Samsung Medical's subsidiary has signed an overseas operating contract worth about 949 million yuan [7] - Hongsheng Huayuan's subsidiary is expected to win a bid for a project with Southern Power Grid valued at approximately 975 million yuan [8] - Caesar Travel Industry's controlling shareholder plans to increase company shares by 10 to 20 million yuan [9] - Daikin Heavy Industry's net profit for 2025 is expected to grow by 132.82%, with a proposed dividend of 0.87 yuan per share [10]

证券代码：601567 证券简称：三星医疗 公告编号：临 2026-006 宁波三星医疗电气股份有限公司 关于子公司签订海外经营合同的公告 宁波三星医疗电气股份有限公司（以下简称"公司"）下属全资子公司 NINGBO SANXING ELECTRIC (SWEDEN) AB（以下简称"三星瑞典"）签订荷兰 Enexis 电 力局变压器框架合同，合同金额总计 1.17 亿欧元，约合 9.49 亿人民币。具体情况如 下： 一、交易概述 三星瑞典签订荷兰 Enexis 电力局变压器框架合同，公司作为供应商，提供油浸 式变压器产品，合同金额总计 1.17 亿欧元，约合 9.49 亿人民币。 二、合同对方当事人情况 公司名称：Enexis Netbeheer B.V. 注册时间：2009 年 主营业务：荷兰配电网运营商/配电系统运营商（DSO），在其负责的地区建设、 维护、运营与扩展电力与天然气配电网络，并向客户提供电力与天然气的输配服务 是否与公司存在关联关系：公司及子公司与 Enexis Netbeheer B.V.不存在关联关 系 合同类型：海外经营合同 项目名称：荷兰 Enexis 电力局变压器框架合同 合同金 ...

Core Viewpoint - On February 26, brokerages provided target prices for listed companies, with notable increases for Hongsoft Technology, China Railway, and Yifan Pharmaceutical, showing target price increases of 47.71%, 34.96%, and 32.82% respectively, across the IT services, infrastructure, and chemical pharmaceutical industries [1][2]. Group 1: Target Price Increases - Hongsoft Technology received a target price increase of 47.71%, with a new target price of 71.27 CNY [3]. - China Railway's target price increased by 34.96%, with a new target price of 8.30 CNY [3]. - Yifan Pharmaceutical's target price rose by 32.82%, with a new target price of 17.40 CNY [3]. Group 2: Brokerage Recommendations - A total of 27 listed companies received brokerage recommendations on February 26, with China Railway, Bohui Paper, and Zhujiang Beer each receiving one recommendation [2]. - Bohui Paper's rating was upgraded from "Range Trading" to "Buy" by Guotai Junan Securities [5]. Group 3: Rating Adjustments - Two companies had their ratings downgraded: Baolong Technology from "Buy" to "Hold" by Tianfeng Securities, and Haiguang Information from "Buy" to "Range Trading" by Guotai Junan Securities [6][8]. - The companies involved in the downgrades were Baolong Technology and Haiguang Information [8]. Group 4: First Coverage - Six companies received first coverage on February 26, including Matrix Co. and Anfu Technology, both rated "Outperform" by Guotai Junan Securities [10]. - Other companies receiving first coverage included Aorite with a "Buy" rating from Zhongyou Securities, Delijia with a "Buy" rating from Dongwu Securities, and Hanguo Group with an "Increase" rating from Dongguan Securities [10].

Market Performance - During the Spring Festival, developed markets saw a general rise, with MSCI Global up by 1.1%, MSCI Developed Markets up by 1.2%, and MSCI Emerging Markets up by 0.8%[3] - The US 10Y Treasury yield increased significantly, while Japanese yields decreased the most[3] Profit Expectations - US stock earnings expectations were revised upward, with S&P 500 2026 EPS forecast increased from +12.7% to +12.9%[4] - Hong Kong's earnings expectations remained flat, with Hang Seng Index 2026 EPS forecast at +11.1%[4] - Eurozone earnings expectations were revised down from -3.1% to -3.0%[4] Economic Indicators - The Citigroup Economic Surprise Index for the US decreased, influenced by lower-than-expected Q4 GDP growth and uncertainties surrounding tariffs[5] - The European Economic Surprise Index increased, driven by significant growth in German economic output[5] Industry Insights - The lithium carbonate market is expected to tighten due to Zimbabwe's ban on lithium concentrate exports, impacting global supply significantly[13] - In 2025, China imported 1.19 million tons of lithium concentrate from Zimbabwe, translating to a production of 148,800 tons of lithium carbonate[14] Real Estate Market - In Q4 2025, only 19% of cities showed signs of bottoming out in the real estate market, with over 90% of key cities experiencing a year-on-year decline in new home transactions[17] - New home prices are expected to continue declining, with first-tier cities facing a clearing cycle exceeding 23 months[20] Banking Sector - Large banks saw a significant increase in short-term loans, while small banks experienced a slowdown in credit growth, with large banks' short-term loans increasing by 4,197 billion yuan[35] - The overall loan amount decreased by 4,893 billion yuan year-on-year, with large banks and small banks seeing declines of 2,130 billion yuan and 2,763 billion yuan, respectively[38] Company Coverage - Samsung Medical's revenue is projected to reach 14.804 billion yuan in 2025, with a growth rate of 1.4%[40] - The company is expected to maintain a target price of 32.4 yuan, reflecting a 24X PE valuation for 2026[40]

Investment Rating - The report initiates coverage with a rating of "Buy" and sets a target price of 32.40 CNY [4][24]. Core Insights - The company has established a global marketing and operational system for its smart power distribution business, focusing on key markets in Europe, the Middle East, and Latin America, while maintaining a leading position in the domestic market [2][12]. - The company is expected to achieve total revenues of 14.80 billion CNY in 2025, with a year-on-year growth rate of 1.4%, and net profit attributable to shareholders of 1.73 billion CNY, reflecting a decrease of 23.3% [23]. Summary by Sections Financial Summary - Total revenue projections for 2025-2027 are 14.80 billion CNY, 16.27 billion CNY, and 18.49 billion CNY, with growth rates of 1.4%, 9.9%, and 13.6% respectively [10][23]. - Net profit attributable to shareholders is forecasted at 1.73 billion CNY, 1.90 billion CNY, and 2.20 billion CNY for the same period, with changes of -23.3%, 9.5%, and 16.1% respectively [10][23]. - Earnings per share (EPS) are expected to be 1.23 CNY, 1.35 CNY, and 1.57 CNY for 2025, 2026, and 2027 [10][23]. Business Operations - The company has a global presence with 8 production bases and over 40 sales centers, covering more than 70 countries and regions [16]. - The overseas distribution business has made significant strides, particularly in Europe, the Middle East, and Latin America, with recent contracts in Hungary, Romania, and Kyrgyzstan [17][18]. - The domestic power distribution business remains strong, focusing on local grid projects and expanding into new customer segments, including renewable energy and data centers [19]. Market Position - The company is recognized as the Chinese firm with the most extensive coverage in Europe, operating in 16 countries [16]. - The overseas revenue for the smart power distribution segment reached 1.495 billion CNY in the first half of 2025, marking a year-on-year increase of 50.89% [19]. - The overall order backlog as of the end of Q3 2025 was 17.914 billion CNY, reflecting a year-on-year growth of 14.69% [19].

Core Viewpoint - Samsung Medical confirmed its actual controllers are Mr. Zheng Jianjiang and Ms. He Yiju, with Aux Group Co., Ltd. being the controlling shareholder of the company [2] Group 1 - The company provided clarification on its ownership structure in response to investor inquiries on an interactive platform [2] - The information regarding the actual controllers and the controlling shareholder is available in the company's periodic reports [2]